A rare case of intravascular epithelioid hemangioendothelioma of the cephalic vein treated with surgery and postoperative radiation therapy: a case report and review of the literature

Maria Paola Ciliberti*, Raffaella Caponio, Antonio Pascali, Gabriele Matichecchia and Marco Lioce

Abstract

Introduction: Epithelioid hemangioendothelioma (EHE) is a rare endothelial tumor with an intermediate grade of malignancy. Few cases of primary vascular hemangioendothelioma have been described in the literature. Surgery is the treatment of choice, but radiation therapy and chemotherapy should also be considered in particular cases.

Case presentation: We present the case of a 44-year-old Caucasian woman affected by EHE of the cephalic vein, treated by complete surgical removal of the mass and postoperative local radiation therapy. At 5-year follow-up, our patient is alive, with no signs of local or distant relapse and with no late radiation-related effects.

Conclusions: Postoperative radiotherapy may play a role in cases in which tumor margins are close or cannot be assessed or when high-risk features are present.

Keywords: Epithelioid hemangioendothelioma, Vascular, Intravascular, Radiotherapy, Cephalic vein, Review

Introduction

Epithelioid hemangioendothelioma (EHE) is a rare type of endothelial tumor that demonstrates an intermediate behavior between benign hemangioma and malignant angiosarcoma. It can occur in soft tissues, bones and visceral organs but also as a primary tumor of the blood vessel. About half of EHE are primary vascular. Differential diagnosis is often difficult, but recent diagnostic tools such as immunohistochemistry and mutation research can be useful for correct characterization. Surgery is the treatment of choice, but adjuvant treatment such as radiation therapy should be considered in the case of high-risk features or when complete removal is not feasible. Although sometimes promising, chemotherapy and antiangiogenic agents do not have a well-established role. We report the case of intravascular EHE occurring in the cephalic vein of a 44-year-old woman, treated by surgery and postoperative radiation therapy (RT).

Case presentation

A 44-year-old Caucasian woman presented with a soft, painless, nonpulsatile, progressively enlarging mass at the level of the antecubital fossa of the left arm. A preliminary ultrasound (US) scan revealed an hypoechoic solid lesion along the cephalic vein, and a subsequent magnetic resonance image (MRI) of the arm confirmed a 2×1cm mass with a hypointense T1 signal and a weakly hyperintense T2 signal along the vein, suggesting a granuloma (Figure 1). Upon physical examination, the mass was mobile and painless; our patient did not present modification of reflexes of her left arm or signs of venous stasis. Our patient then underwent surgical removal of the neoplasm. Histology confirmed the diagnosis of intravenous EHE, defined as a ‘low-grade malignancy with moderate potential to recur locally or to metastasize’. Unfortunately, surgical margins were microscopically involved, so our patient underwent a second surgical operation: a 2cm segment of cephalic vein with a lozenge of skin was excised and replaced with a graft. The definitive histopathologic report confirmed the presence of microscopic residual foci of EHE, with free surgical
margins. Our patient did not show any surgery-related impairment of her left arm functions. A post-surgery US study and MRI scan did not show any residual mass, while a total-body positron emission tomography-computed tomography (PET-CT) did not show any metastatic disease to regional lymph nodes or distant sites. Our patient was then referred to our radiation oncology unit. In consideration of the presence of microscopic disease foci in the second operation specimen and the considerable potential of local recurrence highlighted by the pathologist, our patient underwent RT 4 months after the last surgery. A total dose of 54Gy in 27 fractions was administered with a single 6×6cm field. An 8MeV electron beam was used. Only a mild acute erythema of the irradiated skin was recorded as acute toxicity. During follow-up, our patient underwent MRI or ultrasound scans of the left arm every 6 months and computed tomography (CT) of the thorax and hepatic ultrasound scans every year. Five years after completion of the RT, our patient is alive with no evidence of recurrent or metastatic disease. She presented a Radiation Therapy Oncology Group (RTOG) grade 1 late toxicity in the irradiated skin (pigmentation changes).

Discussion
Hemangioendothelioma (HE) is a vascular neoplasm that shows intermediate biological behavior between benign hemangiomas and highly malignant angiosarcomas. It has the potential to metastatize or recur, although less frequently than classic angiosarcoma.

In the most recent World Health Organization (WHO) Classification [1] of soft tissue sarcoma, HE is included in the group of vascular tumors of the soft tissues and of the bones. Five subtypes of HE of soft tissues are considered: Kaposiform HE (included in the intermediate-rarely metastasizing group) and epithelioid HE, classified as a malignant tumor.

Pseudomyogenic (epithelioid sarcoma-like) HE was the first subgroup introduced in this classification. It usually occurs in young adult men on the limbs, presenting with multiple nodules. The spindle cells are characterized by a t(7;19) translocation [2].

Kaposiform HE is a locally aggressive neoplasm that involves superficial or deep soft tissues of children and teenagers; it has features common to both capillary hemangioma and Kaposi sarcoma, with several solid poorly circumscribed nodules composed of a mixture of small capillaries and solid lobules of endothelial cells arranged in a glomeruloid pattern [3]. It is often associated with consumptive coagulopathy (Kasabach-Merritt syndrome) and lymphangiomatosis [4].

Retiform HE most often occurs in the extremities of young adults as a slowly growing single cutaneous plaque or subcutaneous nodule microscopically characterized by interconnecting arborizing blood vessels arranged in a net-like pattern and minimal cytologic atypia [5]. It has a high frequency of local recurrence but a low metastatic potential [6].

The term ‘composite HE’ indicates a locally aggressive vascular neoplasm of low-grade malignancy showing varying combinations of benign, low-grade malignant, and high-grade malignant vascular components [7].

Epithelioid hemangioendothelioma (EHE) is probably the most aggressive histological subtype. It originates from the endothelium and most often occurs in adults of both sexes, but may rarely also affect children [8]. It was first described by Weiss and Enziger [9], after a review of 14 patients, as an intermediate entity between a benign hemangioma and a high-grade angiosarcoma. The largest series of 137 cases of liver EHE was reported by Makhlouf et al. [10].

Histopathological evaluation is central to the diagnosis of this tumor. Biopsy and immunohistochemical assays are essential to establish a clear diagnosis and to distinguish EHE from other histological types such as carcinoma, infectious processes, metastatic adenocarcinoma such as renal cell carcinoma, Ewing’s sarcoma, telangiectatic osteosarcoma, lymphoma or multiple myeloma (plasmacytoma), hemangioma, epithelioid hemangiendothelioma, and angiosarcoma [11,12]. Corrin et al. first identified the angiogenic nature of these tumors based on the identification of Weibel-Palade bodies in a kind of lung neoplasia previously called ‘intravascular bronchioalveolar tumor’ [13].

Microscopically, EHE produces a typical dense myxochondroid or myxohyaline matrix in which endothelial cells are embedded, arranged in short strings or nests [14]. Endothelial cells are polygonal, round or occasionally fusiform. Usually, mitotic activity is infrequent and nuclei
are uniform, but about one-third of EHE could present anaplastic features with a high nuclear grade, necrosis and high mitotic activity. Due to its variable histological features, differential diagnosis can be difficult. Immunohistochemistry is a useful tool: EHE shows a typical endothelial phenotype, characterized by positivity to CD31, CD34 and von Willebrand factor, and occasionally to cytokeratins [15]. Recently, some studies have proposed new markers for vascular differentiation. For example, nuclear Fli-1, a protein expressed in endothelial cells as well as in T cells and megakaryocytes, was detected in 100% of cases in a series of 13 EHE and demonstrated a better sensitivity than CD34 and better specificity than CD31 [16]. Podoplanin, a transmembrane mucoprotein expressed in lymphatic endothelium, alveolar type I cells, osteoblasts and peritoneal mesothelial cells but not in normal vascular endothelial cells, is a useful marker to distinguish EHE from nonvascular tumors [17,18]. FKBP12, which inhibits Ca2+ and calmodulin-dependent calcineurin function, regulates B and T cell responses, and is expressed in both low- and high-grade vascular tumors, is expressed in well-differentiated areas of EHE [19]. An immunohistochemical panel [20] including FKBP12 combined with CD34 and CD31 allows a 93% diagnostic sensitivity of hemangioendothelioma.

A recurrent translocation t(1;3)(p36.23;q25.1), resulting in the fusion of CAMTA1 on 1p36.23 to WWTR1 on 3q25.1, has recently been identified in most EHE, even if in different sites and grades of malignancy [21,22]; this translocation has not been detected in other pathologies like epithelioid hemangioma, epithelioid angiosarcoma or pseudomyogenic (epithelioid sarcoma-like) HE, which often mimic EHE and make diagnosis more difficult. Another recurrent oncogenic activation secondary to TFE3 gene rearrangements and common fusion with YAP1 appears to be a distinctive subset of EHE occurring in young adults, with a clinically indolent course but a high propensity to metastasis [23]. Fluorescent in situ hybridization (FISH) or RT-PCR analysis for these fusions may be a useful molecular diagnostic tool in challenging diagnoses.

The etiology of EHE is not well known; however, predisposing factors for angiosarcoma have been suggested to include radiation, dysfunctionlzed arteriovenous fistula, foreign bodies, catoid endarterectomy and intravascular prosthesis [24].

After a review of 30 patients with epithelioid EHE, Mentzel et al. found that, although this tumor histologically has low malignancy potential, metastatic disease occurs in 20 to 30% of patients and that overall EHE carries a risk of death of up to 17%; thus, the authors suggested that it should be considered a fully malignant, rather than borderline, vascular neoplasm [25]. Local recurrence occurs in about 10 to 15% of osseous EHE cases [12] after a relatively long period of latency. Half of the metastases occur in locoregional lymph nodes or lungs [26], so periodic CT scans of regional lymph nodes and lungs are recommended in the follow-up. However, patients with metastases could be treated with surgery and then survive for a long time: only 20% of them die due to the disease after 5 years [27] because half of all metastases are in the regional lymph nodes and could be easily controlled with local surgical excision [28]. Prognosis of EHE remains better than that of classic angiosarcoma, although it often remains variable and unpredictable.

Deyrup et al. analyzed 49 patients with EHE in an attempt to identify a method for stratifying risk of mortality. In univariate and multivariate analysis, increasing mitotic activity and size were significantly associated with higher mortality, while tumor site, cytologic atypia, the presence of necrosis and tumor spindling were not significant. The authors concluded that large tumors (>3cm) with high mitotic activity (>3 mitotic figures per 50 high power fields) had the worst prognosis with a 5-year disease-specific survival of 59% and an increased risk of metastases (up to 25%) [8].

Clinical presentation is variable, depending on the size and location of the tumor. EHE is often asymptomatic, especially when it involves visceral organs such as the lungs or liver. Non-specific correlated symptoms can include fatigue, anorexia, nausea, or poor tolerance to exercise [29]. When a superficial vessel is involved, EHE can present as a painful soft mass.

Radiological assessment is the first approach to identifying EHE. The imaging technique used (MRI, CT, US) depends on the primary site of the tumor. Increased uptake of 18-F-fluorodeoxyglucose (FDG) in this tumor has recently been reported [30].

EHE can affect all vascularized tissues in any site, but most frequently involves superficial or deep soft tissues, bones [31,32] and visceral organs, in particular the liver [33] and lungs [34,35]. Cases of EHE have been described in almost all sites such as the skin [36,37], central nervous system [38-40], meninges [41], lips [42], gingiva [43,44], middle ear [45], thyroid gland [46], salivary glands [47], paranasal sinuses [48,49], breast [50], pleura [51-53], lymph nodes [54], mediastinum [55,56], heart [57-61], retroperitoneum [62], ileum [63-65], peritoneum [66], testis [67], bladder [68,69], penis [70], vulva [71], and so on. In 10% of cases the disease is multifocal [72].

Mortality varies depending on primary tumor site: the mortality rate is 13% for EHE of soft tissues, 31% for EHE of the bone, 43% for EHE of the liver [10] and 65% for EHE of the lung [14].

Primary vascular EHEs represent about 50% of reported cases. They arise from a blood vessel [73], commonly small- to moderate-sized veins, such as the femoral, iliac or jugular veins, but also larger vascular structures such as the aorta or vena cava. Few cases originate from medium- to small-sized peripheral vessels. The intravascular subtypes are extremely rare [74].
Usually, EHEs present clinically as a painless elastic soft mass in the vicinity of a peripheral vessel causing symptoms and signs of deep venous occlusion, ranging from edema of the extremities, weakness and ischemia, to superior vena cava syndrome. Microscopically, they are associated with a blood vessel, usually a medium-sized vein [29], showing first an expansion of the affected blood vessel and then an involvement of the surrounding soft tissues, with a centrifugal proliferation pattern. It is often difficult to make a correct diagnosis in the early phase. This is partly because they are extremely rare and also because their imaging characteristics are nonspecific, resembling inflammatory or atherosclerotic lesions [24]. Ultrasonography is useful to define the morphology and vascularization of these masses and to evaluate blood flow, usually showing intraluminal defects and altered flow patterns, loss of plasticity and velocity increase [75]. On the other hand, MRI can give additional information about the involvement of surrounding soft tissues and cleavage planes, in addition to morphological features [27]. However, definitive radiological diagnosis is often hard, and only histological diagnosis can be conclusive.

Forty-three case reports on primary vascular EHE of both veins and arteries (except the aorta) have been described in the literature (Table 1). The involved vessels were the thoracic aorta [76,77], aortoiliac segment [78], radial artery [27], inferior vena cava [79-81], superior vena cava [82-86], innominate vein [55,87-91], ayzygos vein [92-94], femoral vein [73,74,78,94-98], femoral artery [99] iliac veins [28,100,101], internal carotid artery [24], axillary vein [102], brachial vein [103] or artery [104-107], popliteal artery [108], pulmonary artery [109], occipital artery [110], temporal artery [111], meningeal artery [112], and digital artery [113]. Age of presentation ranged from 11 to 79 years (mean age was 39 years), and the distribution among the two sexes was almost equal, with a slight predominance of the female sex (59% vs. 41%). The diameter of the masses was variable, ranging from 0.5cm to 11cm. Almost all patients underwent surgical removal of the vascular EHE; in four cases resection was not complete, with macroscopic residual mass or microscopic positive margins. After treatment, patients were monitored for follow-up (2 to 108 months). Six patients (14%) developed distant metastases, especially liver and lung metastases, even if this occurrence did not always affect the overall survival when metastasectomy was performed. Three patients (7%) had local relapse, often in the cases treated by incomplete surgical removal; relapse was always treated with a second surgery. Postoperative RT was administered in only five cases, and chemotherapy in three patients.

The treatment options for EHE include surgery, RT, and chemotherapy; new therapies such as antiangiogenetics agents have been also used. Few cases of spontaneous regression of EHE have been reported [114].

When feasible, surgery with free resection margins is the treatment of choice in the management of EHE. For example, partial hepatectomy [115] or orthotopic liver transplantation [116] represent the first treatment in primary hepatic tumors. Embolization of feeding vessels causing spontaneous regression of vascular tumors has been described [117]. When feasible, a wide resection is also recommended in primary bone EHEs. A preoperative selective embolization of involved vertebra may help to reduce intraoperative blood loss [118]. Surgery is the mainstay also in the treatment of primary vascular EHE. When reconstruction of the vessel is necessary, it can be done with prosthetic or autogenous interposition graft replacement [100]. A complete local excision of the neoformation with or without local lymphadenectomy is related to long-term survival.

A few patients have been treated with chemotherapy, often in the metastatic setting, but results are not always encouraging and response of EHE to chemotherapy seems to be low. The mainstay chemotherapeutic agents for metastatic EHE are doxorubicin and fluorouracil. Intensive regimens using combinations of vincristine, doxorubicin, ifosfamide, etoposide and cyclophosphamide have shown an increase in response rate, without an advantage in overall survival [10]. Doxorubicin in the pegylated liposomal formulation seems to lead to better responses [119] and reduce the risk of cardiotoxicity [120].

Due to the endothelial origin of EHE and the good response to therapies with interferon (IFN) alpha [121,122], recent therapeutic approaches have focused on the use of antiangiogenetic agents [123]. Bevacizumab is a humanized monoclonal antibody directed against vascular endothelial growth factor and seems to be an effective and well-tolerated treatment for metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas [124,125]. Thalidomide [126,127], lenalidomide [128], and endostar [129] are believed to have immunomodulatory and antiangiogenic properties; they also seem to be useful in the systemic treatment of EHE. Sorafenib [130] is also providing encouraging evidence of benefit.

Selective radionuclide therapy with intra-arterial injection of Yttrium (Y)-90 microspheres [131], commonly used for unresectable liver metastases and primary liver tumors with hopeful results, has shown some results in unresectable hepatic EHE.

In consideration of the high incidence of local relapse and the moderate radiosensitivity of EHE, RT has been used as adjuvant treatment in some high-risk cases, with good results. Hemangiomas involving the skeletal system have been treated effectively with local RT for many decades with a good long-term local control [132], even when RT is used as the only treatment option, such as in cases of surgically inaccessible sites [133].
| Author       | Year | nr.pt | Sex | Age (yrs) | Artery/vein          | Size (cm) | Primary therapy | Adjuvant therapy | Outcome | Notes                                      | Follow-up (months) |
|--------------|------|-------|-----|-----------|----------------------|-----------|-----------------|-------------------|---------|-------------------------------------------|--------------------|
| Wu et al.    | 2014 | 1     | F   | 58        | Right pulmonary artery | /         | S               | 0                 | No      | NED                                       | 24                 |
| Mlynski et al. | 2013 | 1     | F   | 22        | Femoral vein         | /         | S               | 0                 | No      | M Liver and lung metastases               | 12                 |
| Gundara et al. | 2013 | 1     | M   | 39        | IVC                  | 4.5       | S               | 0                 | No      | NED                                       | 48                 |
| Henton et al. | 2013 | 1     | F   | 39        | Brachial artery      | 5         | S               | 0                 | No      | NED                                       | 12                 |
| Muñoz et al. | 2013 | 1     | M   | 44        | External iliac vein  | 2         | S               | 0                 | No      | NED                                       | 108                |
| Li et al.    | 2013 | 1     | F   | 38        | Innominate vein      | 4.2       | S               | 0                 | CH      | NED                                       | 18                 |
| Osawa et al. | 2012 | 1     | M   | 59        | Internal carotid artery | 8         | S               | 2                 | No      | LR + M Death 6 months after surgery       | 6                  |
| Nutthaki et al. | 2012 | 1     | F   | 42        | Brachial artery      | 1.7       | S               | 0                 | No      | /                                        | /                  |
| De Palma et al. | 2012 | 1     | M   | 47        | Azygos vein          | 1         | S               | 0                 | No      | NED                                       | 12                 |
| Lahon et al. | 2012 | 1     | F   | 29        | SVC                  | 4.5       | S               | 0                 | No      | NED                                       | 10                 |
| Fulton et al. | 2011 | 1     | F   | 30        | Femoral vein         | 4         | S               | 0                 | No      | M Lung metastasis at diagnosis            | 8                  |
| Heldenberg et al. | 2011 | 1     | F   | 32        | Popliteal artery     | 3         | S               | 0                 | No      | /                                        | /                  |
| Henriquez et al. | 2011 | 1     | M   | 31        | IVC                  | 7         | S               | 2                 | CH      | RD Second surgery R0                     | /                  |
| Namaoui et al. | 2011 | 1     | F   | 25        | SVC                  | 8         | S               | 0                 | No      | NED                                       | 6                  |
| Minyi et al. | 2011 | 1     | F   | 50        | Common femoral vein  | 3         | S               | 0                 | No      | NED                                       | 12                 |
| Mansour et al. | 2010 | 1     | M   | 35        | Innominate vein      | 9.5       | S               | 0                 | No      | NED                                       | 30                 |
| Deedar et al. | 2010 | 1     | M   | 53        | Axillary vein        | 5.8       | S               | 0                 | No      | NED                                       | /                  |
| Zhang et al. | 2010 | 1     | F   | 71        | Brachial artery/axillary artery | 6.5   | S               | 1                 | No      | NED                                       | /                  |
| El Demellay et al. | 2009 | 1     | F   | 41        | Temporal artery      | 0.5       | S               | 0                 | No      | NED                                       | 36                 |
| Scordi-Bello et al. | 2009 | 1     | M   | 35        | IVC                  | 11        | S               | 0                 | No      | NED                                       | 10                 |
| Tayeb et al. | 2007 | 1     | F   | 29        | Occipital artery     | /         | S               | 0                 | /       | NED                                       | 12                 |
| Aydin et al. | 2006 | 1     | M   | 77        | Femoral artery       | 6         | S               | 0                 | No      | NED                                       | /                  |
| Kugai* et al. | 2006 | 1     | F   | 69        | Common femoral vein  | /         | S               | /                 | /       | /                                        | /                  |
| Castelli et al. | 2005 | 1     | M   | 26        | Radial artery        | 3         | S               | 0                 | No      | /                                        | /                  |
| Ludovikoski et al. | 2005 | 1     | F   | 11        | Iliac vein           | /         | S               | /                 | M       | Liver metastases                         | 18                 |
| Hampers et al. | 2002 | 1     | F   | 36        | Palmar arch          | 2.5       | S               | 0                 | No      | NED                                       | 12                 |
| Isowa et al. | 2002 | 1     | F   | 41        | Innominate vein      | 3.4       | S               | 0                 | No      | NED                                       | 28                 |
| Schröder et al. | 2001 | 1     | F   | 52        | Femoral vein         | 4         | S               | 0                 | No      | NED                                       | 24                 |
| Charette et al. | 2001 | 1     | M   | 23        | Common femoral vein  | 2         | S               | 0                 | No      | NED                                       | 18                 |
| Ferretti et al. | 1998 | 1     | M   | 79        | SVC                  | 3.5       | S               | 2                 | /       | Biopsy only                              | /                  |
| Reix et al. | 1998 | 1     | F   | 16        | Common femoral vein  | 2         | S               | 0                 | No      | NED                                       | 12                 |
| Moreno et al. | 1998 | 1     | M   | 33        | Innominate vein      | 6         | S               | 0                 | RT      | NED Histiocytoid hemangioma               | 7                  |
| Akashi et al. | 1997 | 1     | F   | 67        | Brachial artery      | 2         | S               | 0                 | No      | NED                                       | 40                 |
Scott et al. [134] treated 14 patients affected by bone EHE with adjuvant or exclusive RT. The median dose administered was 54Gy for the patients treated with RT alone and 62.2Gy for the patients who underwent surgery, with a once daily (1.5 to 2Gy) or twice daily fractionation (1.2Gy). At a median follow up of 10.3 years, the 5-year local control, cause-specific survival, and overall survival rates were 100%, 86%, and 79%, respectively. No cases of late toxicity greater than G1 were recorded, suggesting that RT is a highly effective treatment option for this disease. Yin et al. [135] described a case of complete remission of a cervical spine EHE after the sole administration of 55Gy in 32 fractions over 43 days, using a 6MV photon three-field plan. No severe side effects were recorded, but the authors highlighted the risk of second malignancies. RT was also effective in obtaining a long-term local control when it was administered as adjuvant treatment [136], as in cases when complete surgical removal was not feasible [137,138]. Although re-operation is the treatment of choice in cases of EHE after surgery, RT showed efficacy also when administered as salvage therapy, as in the case of EHE of the mastoid described by Drazin et al.; the total dose administered at recurrence was 59.4Gy in 33 fractions. The patient was free from disease 8 years after surgery [48].

The role of RT in primary vascular EHE has not been established. Few data are available, and it is difficult to summarize guidelines about when this treatment should be performed, that is preoperatively, postoperatively, in the case of incomplete resection, or only at the moment of tumor progression. Hampers and Tomaino described the case of a patient with an EHE that presented as an aneurysm of the superficial palmar arch and third common digital artery [113]. The lesion was completely surgically removed and the patient received postoperative local irradiation to the hand because surgeons and pathologists could not verify tumor-free margins; dose and fraction size were not specified. The patient was free from local or distant recurrence at the 1-year follow-up evaluation. Muñoz et al. described a case of external iliac vein EHE with lymph node metastases treated by surgery and local RT [100]. Unfortunately, doses and volumes were not specified in the report. The patient was alive without local relapse at 8-year follow-up. Tournas and Tomaino described a case of EHE arising from the innominate vein treated with surgery and radiation therapy. The patient was alive at a 4.5-year follow-up without evidence of local relapse [90]. In the experience of Harris et al., an EHE of the external iliac vein with lymph-node involvement in a 32-year-old man was treated with surgery and adjuvant radiotherapy, because microscopic foci of the tumor were seen extending to the margins of the resection. The total dose administered was 66Gy, and the patient was free from relapse after 12 months [28].

**Conclusions**

Primary vascular EHEs are rare and publications in the worldwide literature are almost exclusively case reports.
Primary vascular EHEs can occur in every age group. Surgery is the preferred treatment, when feasible. Chemotherapy is often used in cases of metastatic disease, with ambiguous results. The case reported here suggests that the addition of postoperative RT may be useful in cases where tumor margins are close or cannot be assessed, or those with high-risk features. Unfortunately, EHE behavior often remains unpredictable and unrelated to microscopic findings.

Consent
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations
CT: computed tomography; EHE: epithelioid hemangioendothelioma; FDG: 18-F-fluorodeoxyglucose; FISH: fluorescent in situ hybridization; HE: hemangioendothelioma; IFN: interferon; MRI: magnetic resonance imaging; PET-CT: positron emission tomography-computed tomography; RT: radiation therapy; US: ultrasonography.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
MPC, RC and GM collected our patient clinical information, analyzed the bibliography, drafted and wrote the manuscript. AP and ML reviewed and approved the manuscript before submission. All authors read and approved the final manuscript.

Acknowledgments
We would like to thank Caroline Oakley for her accurate revision.

Received: 26 October 2014 Accepted: 4 March 2015
Published online: 29 April 2015

References
1. Fletcher CDM, Bridge JA, Hodgendoorn PCW, Mertens F. World Health Organization Classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013.
2. Trombetta D, Magnusson L, von Steyern FV, Hornick JL, Fletcher CD, Mertens F. Translocation (7;19)(q22;q13) – a recurrent chromosome aberration in pseudomyogenic hemangioendothelioma? Cancer Genet. 2011;204:211–5.
3. Requena L, Kutzner H. Hemangioendothelioma. Semin Diagn Pathol. 2013;30:29–44.
4. Fernández Y, Bernabeu-Wittel M, García-Morillo JS. Kaposiform hemangioendothelioma. Eur J Intern Med. 2009;20:106–13.
5. Zhang G, Qianjin L, Yin H, Wen H, Yuwen S, Li D, et al. A case of retiform-hemangioendothelioma with unusual presentation and aggressive clinical features. Int J Clin Exp Pathol. 2010;3:528–33.
6. Calonje E, Fletcher CD, Wilson-Jones E, Rosai J. Retiform hemangioendothelioma. A distinctive form of low-grade angiosarcoma delineated in a series of 15 cases. Am J Surg Pathol. 1994;18:115–25.
7. McNab PM, Quigley BC, Glass LF, Jukic DM. Composite hemangioendothelioma and its classification as a low-grade malignancy. Am J Dermatopathol. 2013;35:517–22.
8. Deyrup AT, Tighiouart M, Montag AG, Weiss SW. Epithelioid hemangioendothelioma of soft tissue: a proposal for risk stratification based on 49 cases. Am J Surg Pathol. 2008;32:924–7.
9. Weiss SW, Enzinger FM. Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma. Cancer. 1982;50:970–81.
10. Makhlouf HR, Iskiah KG, Goodman ZD. Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases. Cancer. 1999;85:562–82.
11. Evans HL, Raymond AK, Ayala AG. Vascular tumors of bone: a study of 17 cases other than ordinary hemangioma, with an evaluation of the relationship of hemangioendothelioma of bone to epithelioid hemangioma, epithelioid hemangioendothelioma, and high-grade angiosarcoma. Hum Pathol. 2003;34:680–9.
12. Christodoulou A, Symeonidis PD, Kapoutsis D, Iordanidis F. Primary epithelioid hemangioendothelioma of the lumbar spine. Spine J. 2008;8:385–90.
13. Corrin B, Manners B, Millard M, Weaver L. Histiogenesis of the so-called “intravascular bronchioloalveolar tumour”. J Pathol. 1979;128:163–7.
14. de Albuquerque AKA C, de Oliveira Romano S, Eisenberg ALA. Epithelioid hemangioendothelioma: 15 years at the National Cancer Institute. Literature review. J Bras Patol Med Lab. 2013;49:119–25.
15. Weissfeld A, Moran C. Primary vascular tumors of the lungs: a review. Ann Diagn Pathol. 2010;14:296e308.
16. Gill R, O’Donnell RJ, Honvai A. Utility of immunohistochemistry for endothelial markers in distinguishing epithelioid hemangioendothelioma from carcinoma metastatic to bone. Arch Pathol Lab Med. 2009;133:967–72.
17. Fuji T, Zen Y, Sato Y, Sasaki M, Eromae M, Minato H, et al. Podoplanin is a useful diagnostic marker for epithelioid hemangioendothelioma of the liver. Mod Pathol. 2008;21:125–30.
18. Naqvi J, Ordonez NG, Luna MA, Williams MD, Weber RS, El-Naggar AK. Epithelioid hemangioendothelioma of the head and neck: role of podoplanin in the differential diagnosis. Head Neck Pathol. 2008;2:25–30.
19. Kösemehmetoğlu K, Gedikolu G, Ruaçan S. Morphological and immunohistochemical features of malignant vascular tumors with special emphasis on GLUT1, and FIBP12 expressions. Turkish J Pathology. 2011;27:57–67.
20. Higgins JP, Montgomery K, Wang L, Domaney E, Wamke RA, Brooks JD, et al. Expression of FKBPI2 in benign and malignant vascular endothelium: an immunohistochemical study on conventional sections and tissue microarrays. Am J Surg Pathol. 2003;27:58–64.
21. Mendick MR, Nelson M, Pickering D, Johnsson SL, Seemayer TA, Neff JR, et al. Translocation t(1;3)(p13;33)q25) is a nonrandom aberration in epithelioid hemangioendothelioma. Am J Surg Pathol. 2001;25:684–68.
22. Errani C, Zhang L, Shao SY, Hajdu M, Singer S, Mai RQ, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer. 2011;50:644–53.
23. Antonescu CR, Le Loarer F, Mosquera JM, Bonner A, Zhang L, Chen CL, et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer. 2013;52:775–84.
24. Osawa S, Saito A, Shimizu H, Ogawa T, Watanabe M, Tominaga T. A case of intravascular epithelioid hemangioendothelioma occurring 14 years after coil embolization for an extracranial internal carotid artery aneurysm. J Vasc Surg. 2012;55:2530–3.
25. Mentzel T, Beham A, Calonje E, Katenkamp D, Fletcher CD. Epithelioid hemangioendothelioma of skin and soft tissues: clinicopathologic and immunohistochemical study of 30 cases. Am J Surg Pathol. 1997;21:363–74.
26. Palison B. Epithelioid hemangioendothelioma. Acta Oncol. 1999;38:659–61.
27. Castelli P, Caronno R, Piffaretti G, Tozzi M. Epithelioid hemangioendothelioma of the radial artery. J Vasc Surg. 2005;41:151–4.
28. Harris Jr EJ, Taylor Jr LM, Porter JM. Epithelioid hemangioendothelioma of the external iliac vein: a primary vascular tumor presenting as traumatic venous obstruction. J Vasc Surg. 1989;10:693–9.
29. Ravi V, Patel S. Vascular sarcomas. Curr Oncol Rep. 2013;15:347–55.
30. Treglia G, Ceriani L, Paone G, Ruacan S. Morphological and immunohistochemical features of malignant vascular tumors with special emphasis on GLUT1, and FIBP12 expressions. Turkish J Pathology. 2011;27:57–67.
31. Ker YaG, Marx A, Kaiser A, Ruedinger C, et al. Multifocal epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer. 2013;50:644–53.
32. Antonenson CR, Le Loarer F, Mosquera JM, Bonner A, Zhang L, Chen CL, et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer. 2013;52:775–84.
35. Jang KY, Jin GY, Lee YC, Lee HB, Kang MJ, Choi HY, et al. Pulmonary epithelioid hemangioendothelioma: a tumor presented as a single cavitory mass. J Korean Med Sci. 2003;18:599–602.

36. Resnik KS, Kantor GR, Spielvogel RL, Ryan E. Cutaneous epithelioid hemangioendothelioma without systemic involvement. Am J Dermatopathol. 1993;15:272–6.

37. Quante M, Patel NK, Hill S, Merchant W, Courtauld E, Newman P, et al. Epithelioid hemangioendothelioma presenting in the skin: a clinicopathologic study of eight cases. Am J Dermatopathol. 1998;20:541–6.

38. Noto FE, Scheithauer BW. Primary epithelioid hemangioendothelioma of the brain. Am J Surg Pathol. 1996;20:707–14.

39. Baehring JM, Dickey PS, Bannykh SI. Epithelioid hemangioendothelioma of the suprasellar area: a case report and review of the literature. Arch Pathol Lab Med. 2004;128:1289–93.

40. Zheng J, Liu L, Wang J, Wang S, Cao Y, Zhao J. Primary intracranial epithelioid hemangioendothelioma: a low-proliferation tumor exhibiting clinically malignant behavior. J Neurooncol. 2012;110:19–27.

41. Zheng J, Li P, Ma S, Geng M. Epithelioid hemangioendothelioma of the meninges mimicking metastatic carcinoma: a case report. Clin Neuropathol. 2013;32:224–7.

42. Robinson AA, Tolentino LF, Uyanne J, Melrose R, Calhoun CC. Malignant epithelioid hemangioendothelioma (EHE) of the larynx: report of a case. J Laryngol Otol. 2011;125:185–9.

43. Gordón-Núñez MA, Silva LM, Lopes MF, de Oliveira-Neto SF, Maia AF, Galvão HC. Intraoral epithelioid hemangioendothelioma: a case report and review of the literature. J Oral Pathol Med. 2011;40:151–6.

44. Weidie RK, Mintz SM, Werthemier FW. Primary malignant epithelioid hemangioendothelioma of the gingiva. Report of a case and review of the literature. Arch Oral Biol. 1975;39:103–12.

45. Panda NK, Rao SS, Karuppay S, Vajpeyi K, Singh P. Epithelioid hemangioendothelioma of middle ear masquerading as glosus tumor. Am J Otolaryngol. 2007;28:66–71.

46. Krish K, Hotzer JH, Kocoshcha R, Jalees R, Niederle B, Roko R. Hemangioendothelioma of the thyroid gland–true endothelioma or anaplastic carcinoma? Pathol Res Pract. 1980;170:230–40.

47. Youk O, Erdem H, Mutlu V, Erdogan F, Ataş E, Kantarcı M. Epithelioid hemangioendothelioma of the submandibular gland. Auris Nasus Larynx. 2007;34(2):130–4.

48. Park SY, Lee K, Jo S, Huh CH, Cho KH, Na J. Cutaneous epithelioid hemangioendothelioma presented as an ulcerated areolar mass. J Dermatol. 2014;41:1112–3.

49. Márquez-Medina D, Samarmé-Pérezvargas JC, Tuset-DerAbrain N, Montero-Fernández A, Taberner-Bonastre T, Porcel JM. Multifocal penile epithelioid hemangioendothelioma masquerading as superficial penile vein thrombosis. Urology. 2006;68:673. e1–3.

50. da Silva BB, Lopes-Costa PV, Furtado-Veloso AM, Borges RS, Vulvar epithelioid hemangioendothelioma. Gynecol Oncol. 2007;105:539–41.

51. Haap M, Kötter I, Horger M, Thanner C, Wehrmann M, Häring HU, et al. Disseminated epithelioid hemangioendothelioma mimicking symptoms of systemic vasculitis. Onkologie. 2005;28:429–32.

52. Minyi Y, Xintian H, Weimin L, Mier J. Intravascular epithelioid hemangioendothelioma. Int Angiol. 2011;30:181–4.

53. Rex T, Sevestre H, Sevestri-Pietri MA, Szchita P, Rent J. Primary malignant tumors of the venous system in the lower extremities. Ann Vasc Surg. 1998;12:589–96.

54. Louail B, Vautier-Rodary R, Gondry-Jouet C, Westeel A, Filloux-Morfaux V, Gondry-Jouet C. Intraocular epithelioid hemangioendothelioma mimicking symptoms of systemic vasculitis. Onkologie. 2005;28:429–32.

55. Li XM, Lin XY, Xu HT, Yu JH, Wang L, Fan CF, et al. Mediastinal epithelioid hemangioendothelioma. Interact Cardiovasc Thorac Surg. 2004;3:379–85.

56. Martínez-Medina D, Samarmé-Pérezvargas JC, Tuset-DerAbrain N, Montero-Fernández A, Taberner-Bonastre T, Porcel JM. Multifocal penile epithelioid hemangioendothelioma masquerading as superficial penile vein thrombosis. Urology. 2006;68:673. e1–3.

57. Maia AP, Galvão HC. Intraoral epithelioid hemangioendothelioma of the testis. J Urol. 2001;166:1834.

58. Drazin D, Gandhi R, Slodkowska E, Boulos AS. Epithelioid hemangioendothelioma mimicking metastatic carcinoma. J Clin Pathol. 2008;61:188–90.
giant cells mimicking malignant fibrous histiocytoma. Diagn Pathol. 2013;8:103.

88. Isowa N, Hasegawa S, Mino M, Morimoto K, Wada H. Mediastinal epithelioid hemangioendothelioma resected by hemi-plastoon window technique. Ann Thorac Surg. 2002;74:567–9.

89. Moreno A, Asunción Cañadas M, Minguello J, Torras J. Histiocytoid hemangioendothelioma of the bronchus vein. Pathol Res Pract. 1988;183:785–91.

90. Tousariskiss B, O’Connor WN, Dillon ML. Mediastinal epithelioid hemangioendothelioma. Ann Thorac Surg. 1990;59:680–5.

91. Nataf P, Regnard JF, Solvignon F, Bruneval P, Faucher JN, Levasseur P. Epithelioid hemangioendothelioma of the axillary vein. Arch Mal Coeur Vaiss. 1989;82:1919–22.

92. De Palma A, Pagliarulo V, Ardò N, Loizzi D. Surgical treatment of a rare case of epithelioid hemangioendothelioma of the vein. Interact Cardiovasc Thorac Surg. 2012;14:91–3.

93. Lamovicec J, Sobel HJ, Zidar A, Jerman J. Epithelioid hemangioendothelioma of the anterior mediastinum with osteoclast-like giant cells. Light microscopic, immunohistochemical, and electron microscopic study. Am J Clin Pathol. 1990;93:19–37.

94. Jain A, Fulton JJ. A rare vascular tumor presenting as persistent pain at the site of a chronic DVT. J Vasc Surg. 2011;54(6):1861.

95. Charette S, Nehler MR, Whitehill TA, Gibbs P, Foulk D, Krupski WC. Epithelioid hemangioendothelioma of the common femoral vein: case report and review of the literature. J Vasc Surg. 2001;33:1100–3.

96. Myśliński J, Domont A, Mallos S, Bonvalot S, Fukui. Epithelioid hemangioendothelioma of the femoral vein in a 22-year-old female. EJVES Extra. 2013;25:1–2.

97. Kugai T. Epithelioid hemangioendothelioma of the remnant femoral vein associated with a persistent sciatic vein. Jpn J Vasc Surg. 2006;15:387–90.

98. Schröder A, Peters A, Riepe G, Laurenz A, Meierling S, Mentrzel T, et al. Vascular tumors mimicking sclerotic disease. Vasa. 2001;30:62–6.

99. Aydin H, Koper B, Ereklek S, Sakinci U. Epithelioid hemangioendothelioma on left femoral artery after multiple femoral artery interventions. EJVES Extra. 2006;11:112–4.

100. Muñoz A, Diaz-Perez JA, Romera-Rojas AE, Hernandez E, Martin-Berdazco F. Hemangioendothelioma mimicking a nerve sheath tumor clinically and on imaging. Cardiovasc Thorac Surg. 2012;14:91–3.

101. Ludwikowski B, Jones N. Epithelioid hemangioendothelioma of external iliac vein. Vasc Endovascular Surg. 2013;47:474–8.

102. Gaur S, Torabi A, Ołenicki TJ. Activity of angiogenesis inhibitors in metastatic epithelioid hemangioendothelioma: a case report. Cancer Biol Med. 2012;9:133–6.

103. Scott M, Indelicato DJ, Morris CG, Gibbs C, Scarborough MT, Reith JD, et al. Hemangioma of the liver successfully treated with pegylated liposomal doxorubicin. J Vasc Interv Radiol. 2013;24:257–63.

104. Akça S, Süleymanlar I, Dinçer D, Demirbaş A, Gürkan A, et al. Hepatic epithelioid hemangioendothelioma treated with orthotopic liver transplantation: a case report. Turk J Gastroenterol. 2002;13:221–5.

105. Samuel M, Spitz L. Infantile hepatic hemangioendothelioma: the role of surgery. J Pediatr Surg. 1995;30:1425–9.

106. Ataloton K, Staels E, Bertoni F, Bacchini P, Donati D, Fabbri N, et al. Hemangioendothelioma of the spine. Clin Orthop Relat Res. 2004;418:191–7.

107. Isowa N, Hasegawa S, Mino M, Morimoto K, Wada H. Mediastinal epithelioid hemangioendothelioma as a rare cause of blue toe syndrome. Cardiovasc Thorac Surg. 2014;13:2265–9.

108. Niemelä M, Mäenpää H, Salven P, Summanen P, Poussa K, Laatikainen L, et al. Interferon alpha-2a therapy in 18 hemangioblastomas. Clinical Cancer Res. 2001;7:510–6.

109. Calabrò L, Di Giacomo AM, Atromonte M, Fonsatti E, Mazzei MA, Volterrani L, et al. Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? J Exp Clin Cancer Res. 2007;26:145–50.

110. Toursarkissian B, Özkurt M, Yıldız HS, Kemer V, Yıldız A, Küçük O, et al. Treatment of pulmonary epithelioid hemangioendothelioma with combination chemotherapy: report of three cases and review of the literature. Oncol Lett. 2013;5:1491–6.
137. Watanabe T, Saito N, Shimaguchi H, Fujimaki H, Kamiya M, Nakazato Y, et al. Primary epithelioid hemangioendothelioma originating in the lower petroclival region: case report. Surg Neurol. 2003;59:429–33. discussion 434.

138. Themistocleus GS, Papagelopoulos PJ, Petraki KD, Stilianessi EV, Partsnevelos AA, Sapkas GS. A 23-year-old woman with complete paraplegia and anesthesia below the T8 level. Clin Orthop Relat Res. 2005;430:258–65.

139. Kleer CG, Unni KK, McLeod RA. Epithelioid hemangioendothelioma of bone. Am J Surg Pathol. 1996;20:1301–11.

140. Wold LE, Unni KK, Beabout JW, Ivins JC, Bruckman JE, Dahlin DC. Hemangioendothelial sarcoma of bone. Am J Surg Pathol. 1982;6:59–70.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit